Keywords: Case report; Mucoepidermoid; Cancer; Bronchus; Lung; Egfr; TKIs;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ALK; anaplastic lymphoma kinase; DCTN1; dynactin 1; EGFR; epidermal growth factor receptor; EML4; microtubule-associated protein-like 4; FISH; fluorescence in situ hybridization; GLCI; Guangdong Lung Cancer Institute; HELP; hydrophobic EMAP-like protein;
Keywords: EGFR; TKIs; Monoclonal antibodies; Toxicity; Gastrointestinal cancer; Panitumumab; Cetuximab;
Keywords: Gastrointestinal stromal tumor; GIST; Gastric mass; Abdominal tumor; Tyrosine kinase inhibitor; TKIs; Imatinib; Sunitinib;
Keywords: Dual EGFR/HER2 inhibitors; Resistance; T790M/L858R mutant EGFR; Irreversible inhibitors; ADMET; Absorption/Distribution/Metabolism/Excretion/Toxicity; Cbl; Casitas B-lineage Lymphoma; c-MET; cellular mesenchymal to epithelial transition factor; DM; double
Keywords: Epidermal growth factor receptor; Ethnic disparities; Outcome research; SEER; TKIs;
Keywords: Acute lymphoblastic leukemia; Chronic myeloid leukemia; Ph+; Relapse; TKIs;
Keywords: VEGF; vascular endothelial growth factor; CRC; colorectal cancer; VEGFR; VEGF receptors; PLGF; placental growth factor; HGF; hepatocyte growth factor; Il; Interleukin; Del-1; developmentally-regulated endothelial cell locus 1 protein; FGF; fibroblast grow
ERBB2 mutation: A promising target in non-squamous cervical cancer
Keywords: ICC; invasive cervical cancer; HPV; human papillomavirus; IHC; immunohistochemistry; FISH; fluorescence in situ hybridization; TKIs; tyrosine kinase inhibitors; Cervical cancer; ERBB2 mutation; PIK3CA mutation; KRAS mutation; Targeted therapy;
Multitargeted kinase inhibitors imatinib, sorafenib and sunitinib perturb energy metabolism and cause cytotoxicity to cultured C2C12 skeletal muscle derived myotubes
Keywords: Mitochondria; Complex activities; C2C12 cells; Cytotoxicity; Tyrosine kinase inhibitors; Glucose and nucleoside uptake; BCR; breakpoint cluster region; ABL; Abelson murine leukemia; PDGFR; platelet derived growth factor receptor; VEGFR; vascular endotheli
KRAS-Mutant non-small cell lung cancer: From biology to therapy
Keywords: BATTLE; Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination; BET; bromodomains and extra-terminal domain; CDK; cyclin-dependent kinase; Chk1; checkpoint kinase 1; CI; confidence interval; CUSTOM; Molecular Profiling and Targete
Systematic bioinformatic approaches reveal novel gene expression signatures associated with acquired resistance to EGFR targeted therapy in lung cancer
Keywords: DEGs; Differentially Expressed Genes; ES; effect size; EGFR; epidermal Growth Factor Receptor; FDR; False Discovery Rate; GEO; Gene Expression Omnibus; GSEA; Gene Set Enrichment Analysis; IMEx; International Molecular Exchange; MSigDB; Molecular Signature
COL5A1 may contribute the metastasis of lung adenocarcinoma
Keywords: SCLC; Small-cell Lung Carcinoma; NSCLC; Non-small-cell Lung Carcinoma; TKIs; Tyrosine Kinase Inhibitors; EGFR; Epidermal Growth Factor Receptor; ALK; Anaplastic Lymphoma Kinase; DEGs; Differentially Expressed Genes; GEO; Gene Expression Omnibus; GO; Gene
Up-regulation of YPEL1 and YPEL5 and down-regulation of ITGA2 in erlotinib-treated EGFR-mutant non-small cell lung cancer: A bioinformatic analysis
Keywords: EGFR; epidermal growth factor receptor; NSCLC; non-small cell lung cancer; TKIs; tyrosine kinase inhibitors; GEO; Gene Expression Omnibus; PPI; protein-protein interaction; DEGs; differentially expressed genes; AXL; AXL Receptor Tyrosine Kinase; ZEB1; zin
The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance
Keywords: ABCB1; ATP-binding cassette sub-family B member 1; AML; acute myeloid leukaemia; AMPK; adenosine monophosphate-activated protein kinase; ATM; Ataxia-telangiectasia mutated; AURKA; aurora kinase A; BER; base excision repair; Bim; B-cell lymphoma 2 interact
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors
Keywords: EGFR; WZ4002; Anilinopyrimidine; NSCLC; TKIs; EGFR triple mutant;
Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer
Keywords: ILD; interstitial lung disease; EGFR; epidermal growth factor receptor; TKIs; tyrosine-kinase inhibitors; PD-1; programmed cell death-1; NSCLC; non-small-cell lung cancer; RECIST; Response Evaluation Criteria in Solid Tumors; CT; chest computed tomography
Comparative safety and efficacy of tyrosine kinase inhibitors (TKIs) in the treatment setting of different types of leukemia, and different types of adenocarcinoma
Keywords: TKIs; tyrosine kinase inhibitors; OS; overall survival; PFS; progression free survival; CML; chronic myelogenous leukemia; EGFR; epidermal growth factor receptor; VEGF; vascular endothelial growth factor; PDGFR; platelet-derived growth factor receptors; M
EGFR inhibition in NSCLC: New findingsâ¦. and opened questions?
Keywords: EGFR; Targeted therapy; TKIs; Resistance; Liquid biopsy;
Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells
Keywords: CRM1; chromosome region maintenance 1; EGFR; epidermal growth factor receptor; EMT; epithelial-mesenchymal transition; LMB; leptomycin B; MTT; 3-(4,5-dimetrylthiazol)-2,5-diphenyltetrazolium bromide; NSCLC; non-small cell lung cancer; TKIs; tyrosine kinas
Downregulation of miR-224 and let-7i contribute to cell survival and chemoresistance in chronic myeloid leukemia cells by regulating ST3GAL IV expression
Keywords: CML; chronic myeloid leukemia; BMMC; bone marrow mononuclear cells; MS; mass spectrometry; qRT-PCR; quantitative real time-PCR; ST3Gal; CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase; TKIs; Tyrosine kinase inhibitors; BCRP; breast
Long noncoding RNA HULC promotes cell proliferation by regulating PI3K/AKT signaling pathway in chronic myeloid leukemia
Keywords: CML; chronic myeloid leukemia; TKIs; tyrosine kinase inhibitors; lncRNAs; long non-coding RNAs; HCC; hepatocellular carcinoma; HOX transcript antisense RNA; HOTAIR M1; FBS; fetal bovine serum; FITC; fluorescein isothiocyanate; shRNA; short hairpin RNA; qR
Interaction between the zebrafish (Danio rerio) organic cation transporter 1 (Oct1) and endo- and xenobiotics
Keywords: ADME; absorption, distribution, metabolism and excretion; ASP+; 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide; DAPI; 4â²,6-diamidino-2-phenylindole; DBT; dibutyltin chloride; DMEM; Dulbecco's modified eagle's medium; HEK239; human embryonic kid
The roles of subcellularly located EGFR in autophagy
Keywords: AMPK; AMP-activated protein kinase; ATG; autophagy-related; BCL2; B-cell lymphoma 2; BCL2L1; BCL2 like 1; BNIP3; BCL2/Adenovirus E1B-binding protein Nip3; CME; clathrin-mediated endocytosis; cytoSTAT3; cytoplasmic STAT3; Dsbs; double strand breaks; ECD; e
One-step radiosynthesis of 18F-IRS: A novel radiotracer targeting mutant EGFR in NSCLC for PET/CT imaging
Keywords: 18F-IRS; EGFR; TKIs; PET/CT; Imaging;
Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer
Keywords: EGFR; epidermal growth factor receptor; TKIs; tyrosine-kinase inhibitors; NSCLC; non-small-cell lung cancer; PFS; progression-free survival; FISH; fluorescence in-situ hybridization; IHC; immunohistochemistry; ERCC1; excision repair cross-complementation
AKT inactivation causes persistent drug tolerance to EGFR inhibitors
Keywords: SCLC; small cell lung cancer; NSCLC; non-small-cell lung cancer; TKIs; tyrosine kinase inhibitors; RTK; receptor tyrosine kinase; EGFR; epidermal growth factor receptor; IGF-1R; insulin-like growth factor 1 receptor; FGFR1; fibroblast growth factor recept
Silencing of miR-21 sensitizes CML CD34+ stem/progenitor cells to imatinib-induced apoptosis by blocking PI3K/AKT pathway
Keywords: CML; chronic myeloid leukemia; LSCs; leukemia stem cells; qRT-PCR; quantitative real-time PCR; pAKT; phosphorylated AKT; pCrkl; phosphorylated Crkl; TKIs; tyrosine kinase inhibitors; MiR-21; Imatinib; CML; CD34+ stem/progenitor cells; Apoptosis;
Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence
Keywords: MET; MV-DN30 monovalent antibody; TKIs; Resistance; Drug dependence; MV-DN30; Monovalent DN30; TKIs; Tyrosine kinase inhibitors; HGF; Hepatocyte growth factor; MAPK; Mitogen-activated protein kinase;
Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer
Keywords: EGFR; Epidermal growth factor receptor; NSCLC; Non-small cell lung cancer; RFLP; Restriction fragment length polymorphism; Scorpions ARMS; Scorpion amplified refractory mutation system; TKIs; Tyrosine kinase inhibitors; Epidermal growth factor receptor; T
Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia
Keywords: Dasatinib; Nilotinib; CML; TKIs; Discontinuation
OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance
Keywords: OSI-930; {N-(4-trifluoromethoxyphenyl)3-((quinolin-4-ylmethyl) amino) thiophene-2-carboxamide}; ABC; ATP binding cassette; ABCG2 (BCRP/MXR/ABCP); ABC subfamily G member 2; MDR; multidrug resistance; P-gp; P-glycoprotein; ABCCs (MRPs); ABC subfamily C memb
Multitargeted receptor tyrosine kinase inhibition: An antiangiogenic strategy in non-small cell lung cancer
Keywords: Angiogenesis; NSCLC; TKIs; VEGFR; PDGFR; FGFR;
Cardiotoxicity of novel molecular targeted therapies of cancer
Keywords: Cardiotoxicity; TKIs; Cardiomyocite; VEGF; PDGF; Cardiotossicità ; TKI; Cardiomiocita; VEGF; PDGF;
Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status
Keywords: NSCLC; K-RAS mutations; Front-line chemotherapy; EGFR mutations; TKIs
Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention
Keywords: AFP; alpha-fetoprotein; ANOVA; analysis of variance; ELISA; enzyme-linked immunosorbent assay; FGF19; fibroblast growth factor 19; FGFR; fibroblast growth factor receptor; FRS2α; FGFR substrate protein-2α; GAPDH; glyceraldehyde 3-phosphate dehydrogenase
ErbBs in lung cancer
Keywords: Lung cancer; ErbBs; EGFR; TKIs